ReviewCancer2023
A review of treatment options in HER2-low breast cancer and proposed treatment sequencing algorithm.
Review in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Romanian Consensus Statement for Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (HR+/HER2- mBC) and Triple-Negative Metastatic Breast Cancer (mTNBC).Current oncology (Toronto, Ont.) · 2026Guideline
- Real-world treatment patterns and outcomes in hormone receptor-positive, HER2-low metastatic breast cancer, 2018-2023: a retrospective, observational, US cohort study.Breast cancer research and treatment · 2026Observational
- Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer.Current treatment options in oncology · 2026Review
- Synergy of radiotherapy, focused ultrasound, and immunotherapy in the treatment of brain metastases.Journal of neuro-oncology · 2025Review
- Genetics of Response to ECT, TMS, Ketamine and Esketamine.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2025Review
- Development and clinical evaluation of [European journal of nuclear medicine and molecular imaging · 2025Article
- Challenges & recommendations for identification of human epidermal growth factor receptor -2 (HER2)-low metastatic breast cancer in India: Expert opinion statement.The Indian journal of medical research · 2025Review
- Efficacy and Predictability of Cyclin-Dependent Kinase 4/6 Inhibitors in HER2-Positive Breast Cancer.Cancers · 2025Review
- Article
- Emerging HER2 Targeting Immunotherapy for Cholangiocarcinoma.Oncology research · 2025Review
- Somatic Mutations in Latin American Breast Cancer Patients: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2024Review
- Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast Cancer.Breast cancer (Dove Medical Press) · 2024Article
- Challenges in HER2-low breast cancer identification, detection, and treatment.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2024Review
- Comparative Analysis and Future Prospects of Human Epidermal Growth Factor Receptor 2 (HER2) and Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted Antibody-Drug Conjugates in Breast Cancer Treatment.Breast cancer (Dove Medical Press) · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
The expansion of the spectrum of human epidermal growth factor receptor 2 (HER2)-status to HER2-low, defined as HER2 expression of 1+ by immunohistochemistry (IHC) or 2+ by IHC without gene amplification, has made a major impact in the field of oncology. The HER2-low expression has emerged as a targetable biomarker, and anti-HER2 antibody-drug conjugate trastuzumab deruxtecan has shown significant survival benefit in pretreated metastatic HER2-low breast cancer (BC). With these recent data, the treatment algorithm for hormone receptor-positive and triple-negative BC needs to be reconsidered, as approximately half of these BCs are HER2-low. Although there are different therapeutic agents for hormone receptor-positive and hormone receptor-negative HER2-low BCs, there is no consensus regarding the sequencing of these agents. In this article, the treatment options for HER2-low BC are enumerated and a treatment sequencing algorithm based on the current clinical evidence proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.